ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,094Medicare Part D Prescriptions Filled, Including Refills

Rank: 289 out of 1844

$466K Total Retail Price of All Prescriptions

Rank: 418 out of 1844

336 Patients Receiving at Least One Drug in Part D
84%Patients 65 Years and Older
58% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Indiana
Lower avg

Schedule Two
Controlled Substances

7% of this provider’s 336 patients filled at least one prescription for a schedule two drug, compared to an average of 4%.

Schedule Three
Controlled Substances

20% of this provider’s 336 patients filled at least one prescription for a schedule three drug, compared to an average of 15%.

Risky Drugs to Seniors

1% of this provider’s 7,049 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

24% of this provider’s prescriptions were for brand-name drugs, compared to an average of 24%.

Prescription Price

$51 was the average price of a prescription from this provider, compared to $60 among peers.

Prescriptions per Patient

27 is the average number of prescriptions (including refills) per patient, compared to an average of 20.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Indiana
HYDROCODONE-ACETAMINOPHEN 398 299 S3 1 2
OMEPRAZOLE 350 288 2 5
LEVOTHYROXINE SODIUM 279 256 3 1
FUROSEMIDE 267 188 4 7
LISINOPRIL 232 194 5 4
AMLODIPINE BESYLATE 185 172 6 6
ZOLPIDEM TARTRATE 178 141 7 23
METFORMIN HCL 171 114 8 8
SERTRALINE HCL 162 106 9 21
SIMVASTATIN 154 122 10 3
METOPROLOL TARTRATE 152 119 11 11
HYDROCHLOROTHIAZIDE 133 105 12 9
WARFARIN SODIUM 129 119 13 13
GABAPENTIN 126 64 14 15
POTASSIUM CHLORIDE 119 103 15 16
TAMSULOSIN HCL 114 92 16 27
CARVEDILOL 109 84 17 22
PRAVASTATIN SODIUM 102 82 18 10
ATORVASTATIN CALCIUM 101 85 19 12
ISOSORBIDE MONONITRATE ER 96 87 20 59
FLUTICASONE PROPIONATE 89 72 21 50
POLYETHYLENE GLYCOL 3350 84 79 22 39
FLUOXETINE HCL 83 63 23 41
LANTUS 81 42 24 42
LOVASTATIN 79 61 25 44
CARBIDOPA-LEVODOPA 77 61 26 86
DIVALPROEX SODIUM 77 60 26 74
METOPROLOL SUCCINATE 76 76 28 14
CLOPIDOGREL 75 68 29 34
ATENOLOL 73 73 30 17
NOVOLOG 72 59 31 84
GLIPIZIDE 71 43 32 70
TRAZODONE HCL 69 53 33 43
NAMENDA 68 68 34 33
ESCITALOPRAM OXALATE 67 43 35 52
DONEPEZIL HCL 66 66 36 26
LOSARTAN POTASSIUM 64 62 37 24
BACLOFEN 63 24 38 119
CYMBALTA 62 34 39 36
DIOVAN 61 54 40 58
ALLOPURINOL 57 48 41 29
BYSTOLIC 56 56 42 106
CITALOPRAM HBR 54 45 43 19
CRESTOR 54 42 43 30
TRAMADOL HCL 54 49 43 18
GLIMEPIRIDE 51 28 46 35
ZETIA 50 38 47 81
OXYCODONE HCL-ACETAMINOPHEN 50 12 S2 47 83
LYRICA 50 26 47 92
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on March 26, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.